Acute Care Therapeutics for Surgical Settings

Baudax Bio is a pharmaceutical company focused on developing and commercializing innovative products for acute care settings.

About Baudax Bio

We are committed to bringing meaningful therapeutic options to patients, healthcare providers, and payers.  We currently have multiple therapeutic candidates across early, mid and late-stage clinical development, including a FDA approved non-opioid therapy for use in the acute care setting.

About Us

Our Innovative Portfolio & Pipeline

On February 20, 2020, the FDA approved ANJESO (meloxicam) injection, for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.  Our product pipeline contains valuable therapeutic candidates for patients and healthcare providers in acute care settings.

ANJESO (meloxicam) injection

Product Portfolio

Latest News

Baudax Bio Announces Date of Reconvened Annual Meeting of Shareholders

View Press Release

Baudax Bio Announces Date of Reconvened Annual Meeting of Shareholders

View Press Release

Baudax Bio Reports First Quarter 2022 Financial Results and Business Highlights

View Press Release

Baudax Bio to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022

View Press Release

Baudax Bio to Present at NobleCon18 Investor Conference

View Press Release

Baudax Bio Reports 2021 Fourth Quarter and Annual Financial Results

View Press Release

Baudax Bio to Present at the Oppenheimer 32nd Annual Healthcare Conference

View Press Release

Baudax Bio Initiates Phase IV Clinical Trial Evaluating ANJESO® in Pediatric Patients Following Surgery

View Press Release

Baudax Bio Regains Compliance with NASDAQ Listing Requirements

View Press Release

Baudax Bio Announces Seventh Orange Book Listable Patent for ANJESO®

View Press Release

Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today